In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
This post first appeared in The New York Times – Business. Read the original article.Ozempic Is About to Go Generic in India, China and Canada
The New York Times – Business:
Written by
in
Africa, Canada, China, Delhi (India), Developing Countries, Diabetes, Drugs (Pharmaceuticals), Eli Lilly and Company, Generic Brands and Products, GLP-1 RAs (Drug), Hong Kong, India, Novo Nordisk A/S, Obesity, Ozempic (Drug), Prices (Fares, Fees and Rates), Regulation and Deregulation of Industry, Weight